Beyond Air Inc (XAIR) USD0.0001
Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company. The Company is engaged in developing a nitric oxide (NO) generator and delivery system through its LungFit platmorfm that is capable of generating NO from ambient air. Its pipeline includes LungFit PH designed to deliver a dosage of NO to the lungs for the treatment of Persistent Pulmonary Hypertension of the Newborn (PPHN), LungFit PRO for the treatment of viral lung infections for adults, which is commonly caused by rhinovirus, respiratory syncytial virus (RSV) and influenza virus and LungFit GO for the treatment of rare and serious pulmonary disease associated with increased morbidity and mortality called Nontuberculous mycobacteria (NTM) lung infection.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.